<DOC>
	<DOCNO>NCT02606253</DOCNO>
	<brief_summary>Broad Objectives : To determine comparative efficacy commonly employ strategy overcome loop diuretic resistance add concomitant loop diuretic hospitalize decompensated heart failure patient hypervolemia Specific Aims : 1 . Compare 48-hour weight change either intravenous chlorothiazide oral tolvaptan compare standard-of-care oral metolazone combine standardized loop diuretic dosing diuretic resistance decompensated heart failure 2 . Compare adverse effect electrolyte depletion renal function change intravenous chlorothiazide oral tolvaptan compare standard-of-care oral metolazone combine standardized loop diuretic dosing diuretic resistance acute heart failure 3 . Pharmacoeconomic analysis direct cost intravenous chlorothiazide oral tolvaptan compare standard-of-care oral metolazone combine standardized loop diuretic dosing diuretic resistance acute heart failure The investigator conduct dual center , randomize , double-blind , double-dummy , parallel design trial comparing : oral metolazone , intravenous chlorothiazide , oral tolvaptan , combination loop diuretic 60 patient hospitalized hypervolemic decompensated heart failure display loop diuretic resistance .</brief_summary>
	<brief_title>Comparison Oral Intravenous Thiazides v Tolvaptan Diuretic Resistant Decompensated Heart Failure</brief_title>
	<detailed_description>Background : The investigator aim evaluate optimal regimen restore diuretic efficacy patient decompensated heart failure demonstrate loop diuretic resistance , guideline-based recommendation weak secondary lack evidence . By compare efficacy , cost , adverse effect currently recommend therapy test novel diuretic combination , investigator augment dearth data exist regard clinical challenge . Current heart failure guideline recommend addition thiazide diuretic , list either oral metolazone intravenous chlorothiazide , loop diuretic therapy strategy overcome loop diuretic resistance . At equipotent dos , two therapy differ 250 fold cost . To date , prospective trial compare efficacy two commonly utilized therapy . Tolvaptan , oral vasopressin 2 receptor antagonist , could restore diuretic efficacy use combination loop diuretic . While safety combination establish EVEREST trial , tolvaptan formally study limited capacity combination therapy restore loop diuretic resistance . Hypokalemia common adverse effect combine thiazide loop diuretic , increase risk atrial ventricular arrhythmias population already high risk . Hypokalemia report combination tolvaptan loop diuretic , likely due tolvaptan 's distinctive mechanism action . This potential benefit could provide tolvaptan unique advantage combination diuretic therapy environment electrolyte monitor routinely perform patient frequent arrhythmic event . Methods : All patient provide informed consent prior enrollment . All patient randomize 1:1:1 fashion use electronic randomization tool embed REDCAP . All patient start 2L/day fluid restriction 2g/day sodium restriction . Decisions regard initiation , titration , discontinuation standard heart failure medication ( Angiotensin Converting Enzyme Inhibitors , Angiotensin Receptor Blockers , Aldosterone Antagonists , Beta Blockers , digoxin , hydralazine , nitrate ) leave discretion treat physician . Patients randomize either intravenous chlorothiazide 500mg IV Q12H + oral placebo capsule Q12H intravenous placebo infusion Q12H + capsule contain either oral metolazone 5mg PO Q12H oral tolvaptan 30mg daily placebo capsule even dose . ( Relative potency : Metolazone 100 fold potent chlorothiazide ) All electrolyte repletion , loop diuretic dose titration , concomitant therapy enhance diuresis need utilized provider 's discretion . To prevent confound heterogeneity diuretic treatment approach , step care algorithm similar CARRESS-HF trial utilized loop diuretic , initial dos subsequent dose change , concomitant inotropes vasodilator . A minimum furosemide equivalent dose 580mg/24hrs ( 100mg IV bolus + 20mg/hr infusion rate ) must order enrollment . Outcomes The primary outcome 48-hour stand scale weight change ( kg ) enrollment among metolazone , intravenous chlorothiazide , tolvaptan arm , use metolazone group comparator group group . Secondary outcome , use metolazone comparator group , : - 48 hour net urine output ( ml ) - mean change serum creatinine , , blood urea nitrogen , eGFR 24 hour , 48hours , hospital discharge - mean change diuretic efficiency 24 48 hour baseline value enrollment - mean change serum potassium 24 48 hour baseline value enrollment - mean change serum sodium 24 hour , 48hrs , discharge baseline value enrollment - cumulative dose potassium ( mEq ) magnesium ( g ) supplementation administer 24 48 hour - incidence severe hypokalemia - need escalation study-directed loop diuretic therapy 24 48 hour - addition vasoactive inotropic medication 24 48 hour - Treatment failure ( definition ) - Patient-scored congestion visual analog scale score baseline , 24 48 hour - new cardiac arrhythmia ( atrial ventricular ) study period - receipt inotropic therapy , dopamine , nitroglycerin ; requirement ultrafiltration hemodialysis index hospitalization - in-hospital mortality - pharmacoeconomic analysis direct cost arm include cost : study medication , additional non-trial protocol laboratory analysis cost related monitoring electrolyte , treatment study medication relate adverse effect ( arrhythmia , hypotension , electrolyte repletion ) , escalation loop diuretic therapy dos , addition additional therapy suboptimal diuresis ( inotropic therapy , vasodilator ) , new initiation renal replacement therapy ( hemodialysis ultrafiltration ) . Study Definitions - Urine output : Total urine volume ( ml ) time study enrollment 48 hour - Hypokalemia : Serum potassium value &lt; 3.5mEq/L - Severe Hypokalemia : Serum potassium value &lt; 3.0mEq/L - Hyponatremia : Serum sodium value &lt; 135mEq/L - Severe Hyponatremia : Serum sodium value &lt; 130mEq/L decrease 5mEq/L enrollment serum sodium - Overcorrection serum sodium : increase serum sodium baseline &gt; 12mEq/L 24 hour , increase &gt; 8mEq/L 12 hour , receipt intravenous fluid symptom overcorrection serum sodium regardless numerical rise - Hypomagnesaemia : Serum magnesium value &lt; 2mEq/L - Diuretic efficiency = 24hr urine output/ 24hr Lasix equivalent milligram - Weight : Standing weight scale use baseline weight measurement - New Atrial Arrhythmia : A `` new '' diagnosis atrial arrhythmia ( include atrial fibrillation , atrial flutter , ectopic atrial tachycardia ) last &gt; 30 second OR atrial arrhythmia cause hemodynamic instability ( MAP &lt; 60 require intervention ) - New Ventricular Arrhythmia : Ventricular tachycardia lasting longer 30 second , frequent non-sustained VT cause hemodynamic instability MAP &lt; 60 mmHg require intervention &gt; 1 intra-cardiac defibrillation external cardiac defibrillation shock ventricular fibrillation require defibrillation - Hypotension : SBP &lt; 85 2 repeat measurement within 30 minute last least 30 minute symptomatic hypotension necessitate clinical intervention ( define vasopressor support , intravenous fluid bolus , initiation inotropes ) - Treatment failure : Patients require additional non-study diuretic ( spironolactone dose &gt; 75mg/day , eplerenone &gt; 75mg/day , non-study thiazide ( dose metolazone 2.5mg great equivalence ) loop diuretic , systemic acetazolamide ( diuretic indication ) , triamterene , amiloride therapy ) time 48-hour randomization period . These patient consider treatment failure purpose analysis primary endpoint secondary endpoint . - Patients whose cardiologist add inotropic vasodilator medication consider treatment failure . Patients require increase loop diuretic regimen also consider treatment failure . - Medication cost define Redbook average wholesale price time trial reduce inter-institutional price difference improve external validity analysis . Statistical Analysis The investigator collaborate Department Biostatistics Vanderbilt University Medical Center employ best statistical method allow ther study realistic achievable . Power calculation difficult lack prospective trial compare combination diuretic therapy numerous flaw method previous study . The investigator utilize change weight primary outcome weight change utilized primary efficacy outcome landmark heart failure diuretic trial ( CARRESS-HF ) less standard deviation net urine output . In previous study standard deviation weight loss change group vary approximate value 1.6kg . If minimum clinically meaningful difference experimental control mean 1.5kg , investigator able reject null hypothesis population mean experimental control group equal 82.3 % power . The Type I error probability associate test null hypothesis 0.05 . The investigator utilize intention-to-treat univariate Wilcoxon rank sum analysis independent continuous primary outcome variable use metolazone comparison group intravenous chlorothiazide oral tolvaptan . The investigator also perform multivariate linear model adjust analysis primary outcome correct baseline weight loop diuretic regimen .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
	<mesh_term>Metolazone</mesh_term>
	<mesh_term>Chlorothiazide</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>age 18 year old hospital admission hypervolemic decompensated heart failure complicate loop diuretic resistance 24 hour telemetry monitoring inpatient ward basic metabolic panel laboratory assessment twice daily study period Hypervolemia diagnose admit provider either ( ) pulmonary artery catheterization pulmonary capillary wedge pressure great 19mmHg plus systemic physical exam find hypervolemia ( peripheral edema , ascites , pulmonary edema auscultation ) ( ii ) absence pulmonary artery catheterization data 2 follow sign symptom : peripheral edema ascites , jugular venous pressure &gt; 10mmHg , pulmonary edema chest xray . Loop diuretic resistance define provider decision pursue combination diuretic therapy failure reach provider define adequate diuresis ( exceed urine output 2 L past 12 hour ) despite receipt intravenous loop diuretic dose furosemide equivalent least 240mg/day least past 12 hour ( 40mg furosemide = 20mg torsemide = 1mg bumetanide ) . decision pursue hemodialysis nephrologist estimate glomerular filtration rate MDRD equation &lt; 15ml/min/m2 systolic blood pressure &lt; 85mmHg pregnancy serum potassium &lt; 3.0mEq/L serum sodium &gt; 145mEq/L &lt; 130mEq/L severe malnutrition advance liver disease inability perform stand weight inability collect measure urine either foley catheter urine collection container concomitant therapy strong CYP3A4 inhibitors/inducers ( systemic ketoconazole , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir , nefazodone , rifampin , rifabutin , rifapentine , phenytoin , phenobarbital , carbamazepine , St. John 's Wort ) concomitant therapy pglycoprotein inhibitor ( cyclosporine , erythromycin , tacrolimus , dronedarone , quinidine , verapamil ) nonstudy diuretic ( spironolactone dose &gt; 75mg/day , eplerenone &gt; 75mg/day , nonstudy thiazide loop diuretic , systemic acetazolamide , triamterene , amiloride therapy ) thiazides administration previous 24 hour prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>loop diuretic</keyword>
	<keyword>thiazide diuretic</keyword>
	<keyword>vasopressin antagonist</keyword>
	<keyword>diuretic resistance</keyword>
	<keyword>heart failure</keyword>
</DOC>